

UNCLASSIFIED

AD NUMBER
ADB274592
NEW LIMITATION CHANGE
TO Approved for public release, distribution unlimited
FROM Distribution authorized to U.S. Gov't. agencies only; Proprietary Info.; May 2000. Other requests shall be referred to U.S. Army Medical Research and Materiel Command, 504 Scott St., Ft. Detrick, MD 21702-5012.
AUTHORITY
USAMRC Ltr, 26 Aug 2002.

THIS PAGE IS UNCLASSIFIED

AD _____

Award Number: DAMD17-98-1-8149

TITLE: Molecular Analysis of the Cripto Growth Factor Receptor

PRINCIPAL INVESTIGATOR: Chaosu E
Michael Shen, Ph.D.

CONTRACTING ORGANIZATION: University of Medicine and Dentistry of New Jersey
Robert Wood Johnson Medical School
Piscataway, New Jersey 08854-5638

REPORT DATE: May 2000

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Distribution authorized to U.S. Government agencies only (proprietary information, May 2000). Other requests for this document shall be referred to U.S. Army Medical Research and Materiel Command, 504 Scott Street, Fort Detrick, Maryland 21702-5012.

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20020124 385

NOTICE

USING GOVERNMENT DRAWINGS, SPECIFICATIONS, OR OTHER DATA INCLUDED IN THIS DOCUMENT FOR ANY PURPOSE OTHER THAN GOVERNMENT PROCUREMENT DOES NOT IN ANY WAY OBLIGATE THE U.S. GOVERNMENT. THE FACT THAT THE GOVERNMENT FORMULATED OR SUPPLIED THE DRAWINGS, SPECIFICATIONS, OR OTHER DATA DOES NOT LICENSE THE HOLDER OR ANY OTHER PERSON OR CORPORATION; OR CONVEY ANY RIGHTS OR PERMISSION TO MANUFACTURE, USE, OR SELL ANY PATENTED INVENTION THAT MAY RELATE TO THEM.


LIMITED RIGHTS LEGEND


Award Number: DAMD17-98-1-8149

Organization: University of Medicine and Dentistry of New Jersey
Robert Wood Johnson Medical School

Those portions of the technical data contained in this report marked as limited rights data shall not, without the written permission of the above contractor, be (a) released or disclosed outside the government, (b) used by the Government for manufacture or, in the case of computer software documentation, for preparing the same or similar computer software, or (c) used by a party other than the Government, except that the Government may release or disclose technical data to persons outside the Government, or permit the use of technical data by such persons, if (i) such release, disclosure, or use is necessary for emergency repair or overhaul or (ii) is a release or disclosure of technical data (other than detailed manufacturing or process data) to, or use of such data by, a foreign government that is in the interest of the Government and is required for evaluational or informational purposes, provided in either case that such release, disclosure or use is made subject to a prohibition that the person to whom the data is released or disclosed may not further use, release or disclose such data, and the contractor or subcontractor or subcontractor asserting the restriction is notified of such release, disclosure or use. This legend, together with the indications of the portions of this data which are subject to such limitations, shall be included on any reproduction hereof which includes any part of the portions subject to such limitations.

THIS TECHNICAL REPORT HAS BEEN REVIEWED AND IS APPROVED FOR PUBLICATION.





REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE May 2000	3. REPORT TYPE AND DATES COVERED Annual (13 Apr 99 - 12 Apr 00)	
4. TITLE AND SUBTITLE Molecular Analysis of the Cripto Growth Factor Receptor			5. FUNDING NUMBERS DAMD17-98-1-8149	
6. AUTHOR(S) Chaosu E Michael Shen, Ph.D.				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of Medicine and Dentistry of New Jersey Robert Wood Johnson Medical School Piscataway, New Jersey 08854-5638 E-MAIL: e@cabm.rutgers.edu			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			10. SPONSORING / MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES				
12a. DISTRIBUTION / AVAILABILITY STATEMENT Distribution authorized to U.S. Government agencies only (proprietary information, May 2000). Other requests for this document shall be referred to U.S. Army Medical Research and Materiel Command, 504 Scott Street, Fort Detrick, Maryland 21702-5012.				12b. DISTRIBUTION CODE
13. ABSTRACT (Maximum 200 Words) Although <i>Cripto</i> was the first member of the <i>EGF-CFC</i> gene family to be identified, its biochemical function has been poorly understood. The function of <i>Cripto</i> was initially of interest because its overexpression was found in approximately 80% of human breast carcinomas, as well as in colorectal and pancreatic cancers. Recent genetic data from mouse and zebrafish studies indicates that EGF-CFC proteins function as co-factors or co-receptors for Nodal, a member of the transforming growth factor-beta family. In my ongoing work, I have expressed soluble Nodal and Cripto proteins in conditioned media from transfected mammalian cells, and have used a co-immunoprecipitation approach to detect a binding interaction between Nodal and EGF-CFC proteins. These biochemical studies should contribute to understanding the molecular mechanism of Cripto activity in mammary development and tumorigenesis.				
14. SUBJECT TERMS Breast Cancer			15. NUMBER OF PAGES 10	
			16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	

NSN 7540-01-280-5500

Standard Form 298 (Rev. 2-89)
Prescribed by ANSI Std. Z39-18
298-102

Table of Contents

Cover	
SF 298	Page 2
Table of Contents	Page 3
Introduction	Page 4
Body	Page 4
Key Research Accomplishments	Page 7
Reportable Outcomes	Page 7
Conclusions	Page 8
References	Page 8
Appendices	N/A

Introduction:

Cripto encodes an extracellular protein that is a member of the *EGF-CFC* gene family. Previous studies have suggested that *Cripto* may be involved in human breast carcinogenesis (Salomon et al. 1999), particularly since *Cripto* is consistently overexpressed in approximately 80% of human breast cancers, but not in adjacent normal breast tissue (Qi et al. 1994). Other studies have shown that *Cripto* displays transforming activity when overexpressed in NOG-8 mouse mammary epithelial cells (Ciardiello et al. 1991). In addition, experiments using refolded *Cripto* peptide have shown that *Cripto* can induce tyrosine phosphorylation of the SH2 adapter protein Shc in HC-11 mammary epithelial cells, resulting in increased association of Shc with Grb2 and elevated MAPK kinase activity (Kannan et al. 1997). To elucidate the potential role of *Cripto* in breast development and tumorigenesis, I have been investigating the molecular mechanisms of *Cripto* protein action, with the objective of identifying a putative *Cripto* receptor(s).

Body:

Review of recent work in the field:

In contrast to previous models for *Cripto* protein as a growth factor (Salomon et al. 1999), recent evidence from molecular genetic studies in our lab and others indicates that EGF-CFC proteins act as essential co-factors for Nodal protein. The *Nodal* gene encodes a signaling factor that is a divergent member of the TGF-beta superfamily, and displays a mutant phenotype similar to that for *Cripto* (Zhou et al. 1993; Conlon et al. 1994). Genetic evidence also suggests that Nodal signals through Activin receptors and the Smad2 pathway (Collignon et al. 1996; Oh and Li 1997; Gu et al. 1998; Nomura and Li 1998; Waldrip et al. 1998). However, there is no biochemical evidence at present to show that Nodal protein directly interacts with Activin receptors or *Cripto*.

These studies have led to the proposal that Nodal and EGF-CFC proteins are inactive by themselves, while in combination their activity is equal to that of Activin (Gritsman et al. 1999). Furthermore, the phenotypes of both *Cripto* and *Cryptic* knock-out mice can be readily interpreted as resulting from defects in *Nodal* signaling (Ding et al. 1998; Yan et al. 1999). These data can be summarized in terms of a possible regulatory pathway for *Nodal* and *EGF-CFC* activities (Fig. 1). In this case, the EGF-like growth factor activities documented for *Cripto* protein might represent cross-talk between EGF receptor and SMAD2 signaling pathways (de Caestecker et al. 1998; Kretzschmar et al. 1999).




Figure 1. Potential regulatory role of *EGF-CFC* proteins in the *Nodal* signal transduction pathway. Nodal signals through Activin receptors and the Smad2 pathway but requires EGF-CFC family proteins as co-factors. It is important to note, however, that this pathway does not exclude the possibilities that EGF-CFC proteins could act as co-factors for other members of the TGF-beta superfamily, or could also act through an unrelated signaling pathway.

Technical Objective I: Expression patterns of *Cripto* and *Cripto* receptor

Strategy: In my original grant application, I proposed to survey the distribution of endogenous *Cripto* expression as well as *Cripto*-alkaline phosphatase (AP) fusion protein binding

sites in normal mammary tissue obtained from virgin, pregnant, lactating, and involuting mice. In particular, since it had been shown that human Cripto protein (hCripto) can bind with high affinity to a range of mammary epithelial cell lines, including MDA-MB-453, SK-BR-3 human breast cancer cells and normal mouse HC-11 cells (Brandt et al. 1994; Kannan et al. 1997), I hypothesized that these cell lines expressed putative Cripto receptors.

Results: To examine the expression of *Cripto* at various stages of mammary development, I employed RT-PCR and ribonuclease protection assays to analyze mammary glands from virgin, pregnant, lactating, and regressing stages. As described in my previous annual report, these results indicated that *Cripto* is expressed at extremely low levels throughout mammary development, with slightly elevated expression during pregnancy and lactation. In addition, I found that the binding sites detected for Cripto-AP fusion proteins on HC-11 mammary epithelial cells are likely to correspond to heparan sulfate proteoglycans, and not to signal-transducing receptors. Therefore, I have not pursued further AP-Cripto binding studies on mammary tissue, as originally proposed, but instead have focused on biochemical studies of Cripto binding interactions. Thus, my studies have addressed Task 1 of Technical Objective I in the original Statement of Work, but the lack of evidence for authentic receptor interactions do not support further studies in several lines of MMTV transgenic mice (Task 2 in the Statement of Work).

Technical Objective II: Cloning and characterization of the *Cripto* receptor

Strategy: In my original proposal and Statement of Work, I described a methodology to clone putative Cripto receptors using AP-fusion protein reagents to screen expression libraries. However, since current genetic evidence indicates that Cripto is required for Nodal function and may represent a co-receptor for Nodal, I have decided to focus on the analysis of Cripto interacting proteins using a co-immunoprecipitation approach. In particular, I have undertaken to produce Cripto and Nodal proteins in cell culture, and examine the biochemical interactions between Cripto and Nodal proteins.

Results: Previous studies have shown that zebrafish Oep is a secreted, membrane associated protein. Its association with the cell membrane is mediated by the C-terminal hydrophobic domain since C-terminal truncated Oep can be released from cell membrane (Zhang et al. 1998). To determine if this is the same case for Cripto, we performed cellular fractionation experiments, using insect cells infected with baculoviruses expressing a secreted Cripto protein fused at its N-terminus to glutathione-S-transferase (GST) (Fig. 2). By Western blotting using a specific anti-Cripto antiserum, I found that that purified plasma membrane fractions contained both full-length and C-terminal truncated forms of the GST-Cripto fusion protein. In contrast, the conditioned media from infected cells contained high levels of the truncated GST-Cripto protein, but very low levels of the full-length protein. These results suggested that like Oep, full-length Cripto is also a membrane associated protein, and C-terminal truncated Cripto proteins can be secreted into culture supernatants.




Figure 2. Detection of Cripto protein in plasma membrane fractions and culture supernatants prepared from baculovirus-infected insect cells by Western blotting using anti-Cripto antiserum. Arrows at right indicate positions of full-length and truncated GST-Cripto fusion proteins. For expression of GST-Cripto fusion proteins, cDNAs corresponding to a full-length or C-terminal truncated Cripto were cloned into the *pAcSecG2T* transfer vector (Pharmingen), which contains a *gp67* signal sequence for high-level secretion, and generates an N-terminal fusion with GST. Baculovirus stocks were prepared in Sf9 insect cells and used to infect High-5 insect cells (Invitrogen). Plasma membrane fractionation was performed essentially as described (Ozols 1990; Storrie and Madden 1990). The absence of contaminating endoplasmic reticulum in the plasma membrane fractions was confirmed using assays for cytochrome *b₅* reductase.

To study Nodal protein function, I have made plasmid constructs to express secreted processed Nodal protein in mammalian cells. For this purpose, I have made two constructs, one for expression of a wild-type epitope-tagged Nodal protein, and a second for a chimeric Nodal protein with a heterologous BMP-4 prodomain. I have found that both wild-type and chimeric Nodal proteins can be secreted and processed by 293T cells. Thus, while Nodal protein is not processed successfully in transfected COS cells (data not shown), a cleaved product of the expected size can be found in the culture supernatant of transfected 293T cells (Fig.3). This may reflect differential expression of the specific pro-protein convertase(s) required for Nodal processing (Constam and Robertson 1999).





Figure 3. Preparation of processed Nodal protein in mammalian cells. Plasmid constructs that encode a chimeric BMP4-Nodal and a full-length wild-type Nodal with a FLAG tag at their C-terminus were used to transfect 293T cells. Culture supernatants were collected, concentrated 10-fold and used for Western blotting with a FLAG monoclonal antibody (Sigma). Positions of size standards at 50.3, 37.6, 25.4, 20, 14, and 9.3 kDa are indicated.

In order to detect interaction between Cripto and Nodal proteins, I performed co-immunoprecipitation assays using epitope-tagged Cripto and Nodal proteins produced in culture supernatants of transfected 293T cells. In the experiment shown in Fig. 4, I incubated HA-tagged Cripto protein with FLAG-tagged Nodal protein (either as a chimeric BMP-Nodal or a unmodified wild type Nodal) in solution, and immunoprecipitated with anti-HA monoclonal antibody-coupled beads. Western blotting using an anti-FLAG monoclonal antibody showed that processed mature Nodal protein can be co-immunoprecipitated together with Cripto protein.

Figure 4. Co-immunoprecipitation assay for interaction between Cripto and Nodal proteins. Cripto-HA and Nodal-FLAG proteins were produced in culture supernatants of transiently transfected 293T cells and were concentrated 8-fold. After incubation, protein complexes were immunoprecipitated by anti-HA monoclonal antibody-coupled beads (Covance), the beads washed 4 times with 1x PBS/0.1% NP-40, then immunoprecipitated complexes were resolved on a 12% SDS-PAGE gel and Western blotted using an anti-FLAG monoclonal antibody (Sigma). Positions of size standards at 81.6, 61.5, 50.8, 37.6, 25.4, 20, 14, and 9.3 kDa are indicated.



My experiments have provided preliminary evidence for a direct binding interaction between Cripto and Nodal. I am currently extending these results by investigating the interaction of Nodal protein with other members of the EGF-CFC family, and with various mutant forms of Cripto. I am also investigating whether a Nodal-Cripto protein complex is able to bind to a soluble extracellular domain of ActRIIB, and are attempting to establish a cell culture assay for Nodal activity using published assays for Activin activity. In summary, although I have not pursued the specific experiments proposed in Tasks 1 and 2 of Technical Objective II in the original Statement of Work, I have successfully identified a Cripto-interacting protein (Task 3 of Technical Objective II in the Statement of Work).

Key Research Accomplishments:

- I have expressed soluble Cripto and Nodal proteins in conditioned media from transfected mammalian cell lines for analyses of their activities and potential biochemical interactions.
- Co-immunoprecipitation analyses of these proteins has provided evidence of a direct binding interaction.
- My findings raise the possibility that *Cripto* overexpression in human breast cancer may result in de-regulation of TGF-beta signaling pathways.

Reportable Outcomes:

Published manuscripts:

None.

Meeting abstracts:

Shen, M. M., E, C., Saplakoglu, U., Yan, Y.-T., and Ding, J. (2000). Functional analysis of *EGF-CFC* genes in mouse development indicates their essential role in Nodal signaling. Era of Hope Department of Defense Breast Cancer Research Program Meeting. (Atlanta, GA).

E, C., Saplakoglu, U., and Shen, M. M. (2000). Role for Cripto as a cofactor in the Nodal signaling pathway. Era of Hope Department of Defense Breast Cancer Research Program Meeting. (Atlanta, GA).

Personnel supported by this grant:

Chaosu E

Conclusions:

In the past year, important progress has been made in understanding of the molecular basis for Cripto function. Previous studies have suggested that Cripto has growth factor activity, and that addition of exogenous Cripto protein to mammary epithelial cells lines can result in tyrosine phosphorylation of the ErbB4 receptor and activation of the Ras/MAPK signaling pathway. However, since Cripto does not bind to any of the four known members of the *ErbB* receptor family, it has been unclear how Cripto might function as a ligand to activate receptor-mediated signaling. Thus, it has been significant that recent genetic data from mouse and zebrafish studies indicates that EGF-CFC proteins function as co-factors or co-receptors for Nodal.

In my work, I have expressed soluble Nodal and Cripto proteins in conditioned media from transfected mammalian cells to detect a physical interaction between Nodal and EGF-CFC proteins. My data support a direct association between Nodal and Cripto in vivo to facilitate Nodal signaling, presumably through activin receptors. At present, these data do not allow us to distinguish whether Cripto acts as a co-factor or as a co-receptor for Nodal; however, my ongoing studies should be able to resolve this critical issue. Finally, these biochemical studies should contribute to understanding the molecular mechanism of Cripto activity in mammary development and tumorigenesis.

References:

- Ciardiello, F., Dono, R., Kim, N., Persico, M.G., and Salomon, D.S. 1991. Expression of cripto, a novel gene of the epidermal growth factor gene family, leads to in vitro transformation of a normal mouse mammary epithelial cell line. *Cancer Res.* 51: 1051-1054.
- Collignon, J., Varlet, I., and Robertson, E.J. 1996. Relationship between asymmetric nodal expression and the direction of embryonic turning. *Nature* 381: 155-158.
- Conlon, F.L., Lyons, K.M., Takaesu, N., Barth, K.S., Kispert, A., Herrmann, B., and Robertson, E.J. 1994. A primary requirement for nodal in the formation and maintenance of the primitive streak in the mouse. *Development* 120: 1919-1928.
- Constam, D.B. and Robertson, E.J. 1999. Regulation of bone morphogenetic protein activity by pro domains and proprotein convertases. *J. Cell Biol.* 144: 139-149.
- de Caestecker, M.P., Parks, W.T., Frank, C.J., Castagnino, P., Bottaro, D.P., Roberts, A.B., and Lechleider, R.J. 1998. Smad2 transduces common signals from receptor serine-threonine and tyrosine kinases. *Genes Dev.* 12: 1587-1592.

- Ding, J., Yang, L., Yan, Y.T., Chen, A., Desai, N., Wynshaw-Boris, A., and Shen, M.M. 1998. Cripto is required for correct orientation of the anterior-posterior axis in the mouse embryo. *Nature* 395: 702-707.
- Gritsman, K., Zhang, J., Cheng, S., Heckscher, E., Talbot, W.S., and Schier, A.F. 1999. The EGF-CFC protein one-eyed pinhead is essential for nodal signaling. *Cell* 97: 121-132.
- Gu, Z., Nomura, M., Simpson, B.B., Lei, H., Feijen, A., van den Eijnden-van Raaij, J., Donahoe, P.K., and Li, E. 1998. The type I activin receptor ActRIB is required for egg cylinder organization and gastrulation in the mouse. *Genes Dev.* 12: 844-857.
- Kannan, S., De Santis, M., Lohmeyer, M., Riese II, D.J., Smith, G.H., Hynes, N., Seno, M., Brandt, R., Bianco, C., Persico, G., Kenney, N., Normanno, N., Martinez-Lacaci, I., Ciardello, F., Stern, D.F., Gullick, W.J., and Salomon, D.S. 1997. Cripto enhances the tyrosine phosphorylation of Shc and activates mitogen-activated protein kinase (MAPK) in mammary epithelial cells. *J. Biol. Chem.* 272: 3330-3335.
- Kretschmar, M., Doody, J., Timokhina, I., and Massague, J. 1999. A mechanism of repression of TGFbeta/ Smad signaling by oncogenic Ras. *Genes Dev.* 13: 804-816.
- Nomura, M. and Li, E. 1998. Smad2 role in mesoderm formation, left-right patterning and craniofacial development. *Nature* 393: 786-790.
- Oh, S.P. and Li, E. 1997. The signaling pathway mediated by the type IIB activin receptor controls axial patterning and lateral asymmetry in the mouse. *Genes Dev.* 11: 1812-1826.
- Ozols, J. 1990. Preparation of membrane fractions. *Meth. Enzymol.* 182: 225-235.
- Qi, C.F., Liscia, D.S., Normanno, N., Merlino, G., Johnson, G.R., Gullick, W.J., Ciardiello, F., Saeki, T., Brandt, R., Kim, N., Kenney, N., and Salomon, D.S. 1994. Expression of transforming growth factor alpha, amphiregulin and cripto-1 in human breast carcinomas. *Br. J. Cancer* 69: 903-910.
- Salomon, D.S., Bianco, C., and De Santis, M. 1999. Cripto: a novel epidermal growth factor (EGF)-related peptide in mammary gland development and neoplasia. *Bioessays* 21: 61-70.
- Storrie, B. and Madden, E.A. 1990. Isolation of subcellular organelles. *Meth. Enzymol.* 182: 203-225.
- Waldrip, W.R., Bikoff, E.K., Hoodless, P.A., Wrana, J.L., and Robertson, E.J. 1998. Smad2 signaling in extraembryonic tissues determines anterior-posterior polarity of the early mouse embryo. *Cell* 92: 797-808.
- Yan, Y.-T., Gritsman, K., Ding, J., Burdine, R.D., Corrales, J.D., Price, S.M., Talbot, W.S., Schier, A.F., and Shen, M.M. 1999. Conserved requirement for EGF-CFC genes in vertebrate left-right axis formation. *Genes Dev.* 13: 2527-2537.
- Zhang, J., Talbot, W.S., and Schier, A.F. 1998. Positional cloning identifies zebrafish one-eyed pinhead as a permissive EGF-related ligand required during gastrulation. *Cell* 92: 241-251.
- Zhou, X., Sasaki, H., Lowe, L., Hogan, B.L., and Kuehn, M.R. 1993. Nodal is a novel TGF-beta-like gene expressed in the mouse node during gastrulation. *Nature* 361: 543-547.



DEPARTMENT OF THE ARMY
US ARMY MEDICAL RESEARCH AND MATERIEL COMMAND
504 SCOTT STREET
FORT DETRICK, MARYLAND 21702-5012

REPLY TO
ATTENTION OF:

MCMR-RMI-S (70-1y)

26 Aug 02

MEMORANDUM FOR Administrator, Defense Technical Information
Center (DTIC-OCA), 8725 John J. Kingman Road, Fort Belvoir,
VA 22060-6218


SUBJECT: Request Change in Distribution Statement

1. The U.S. Army Medical Research and Materiel Command has reexamined the need for the limitation assigned to technical reports written for this Command. Request the limited distribution statement for the enclosed accession numbers be changed to "Approved for public release; distribution unlimited." These reports should be released to the National Technical Information Service.

2. Point of contact for this request is Ms. Kristin Morrow at DSN 343-7327 or by e-mail at Kristin.Morrow@det.amedd.army.mil.

FOR THE COMMANDER:

Encl


PHYLLIS M. RINEHART
Deputy Chief of Staff for
Information Management

ADB274369
ADB256383
ADB264003
ADB274462
ADB266221
ADB274470
ADB266221
ADB274464
ADB259044
ADB258808
ADB266026
ADB274658
ADB258831
ADB266077
ADB274348
ADB274273
ADB258193
ADB274516
ADB259018
ADB231912
ADB244626
ADB256677
ADB229447
ADB240218
ADB258619
ADB259398
ADB275140
ADB240473
ADB254579
ADB277040
ADB249647
ADB275184
ADB259035
ADB244774
ADB258195
ADB244675
ADB257208
ADB267108
ADB244889
ADB257384
ADB270660
ADB274493
ADB261527
ADB274286
ADB274269
ADB274592
ADB274604

ADB274596
ADB258952
ADB265976
ADB274350
ADB274346
ADB257408
ADB274474
ADB260285
ADB274568
ADB266076
ADB274441
ADB253499
ADB274406
ADB262090
ADB261103
ADB274372